ECSP12012167A - Procedimientos para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico - Google Patents
Procedimientos para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídicoInfo
- Publication number
- ECSP12012167A ECSP12012167A ECSP12012167A ECSP12012167A EC SP12012167 A ECSP12012167 A EC SP12012167A EC SP12012167 A ECSP12012167 A EC SP12012167A EC SP12012167 A ECSP12012167 A EC SP12012167A
- Authority
- EC
- Ecuador
- Prior art keywords
- proteasome inhibitors
- procedures
- formation
- cyclodextrin complexes
- peptide proteasome
- Prior art date
Links
- 229940079156 Proteasome inhibitor Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000003207 proteasome inhibitor Substances 0.000 title abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
Abstract
La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida. Dichos procedimientos incrementan considerablemente la solubilidad y la estabilidad de estos inhibidores del proteasoma y facilitan tanto su fabricación como su administración.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644122P | 2012-05-08 | 2012-05-08 | |
| PCT/US2012/055127 WO2013169282A1 (en) | 2012-05-08 | 2012-09-13 | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012167A true ECSP12012167A (es) | 2013-02-28 |
Family
ID=49549072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012167 ECSP12012167A (es) | 2012-05-08 | 2012-09-26 | Procedimientos para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20130303482A1 (es) |
| JP (1) | JP2015516416A (es) |
| KR (1) | KR20150007361A (es) |
| CN (1) | CN103781490A (es) |
| AR (2) | AR087863A1 (es) |
| AU (1) | AU2012238318B2 (es) |
| BR (1) | BR112012028726B1 (es) |
| CA (1) | CA2793894A1 (es) |
| CO (1) | CO6571868A2 (es) |
| CR (1) | CR20120485A (es) |
| CU (1) | CU20120159A7 (es) |
| DO (1) | DOP2012000252A (es) |
| EA (1) | EA201201519A1 (es) |
| EC (1) | ECSP12012167A (es) |
| MA (1) | MA35238B1 (es) |
| MX (1) | MX2012010891A (es) |
| MY (2) | MY196510A (es) |
| PH (1) | PH12012502259A1 (es) |
| SG (1) | SG194417A1 (es) |
| TW (1) | TWI603737B (es) |
| WO (1) | WO2013169282A1 (es) |
| ZA (1) | ZA201207384B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| WO2013123254A1 (en) | 2012-02-15 | 2013-08-22 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| SG11201407337QA (en) | 2012-05-08 | 2014-12-30 | Onyx Therapeutics Inc | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
| EA030957B1 (ru) | 2013-03-14 | 2018-10-31 | Оникс Терапьютикс, Инк. | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| MX372671B (es) | 2013-07-19 | 2020-04-23 | Onyx Therapeutics Inc | Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres. |
| CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
| CN103936828A (zh) * | 2014-05-12 | 2014-07-23 | 苏州科耐尔医药科技有限公司 | 卡非佐米中间体及卡非佐米的制备方法 |
| CN105919972A (zh) * | 2015-12-18 | 2016-09-07 | 重庆两江药物研发中心有限公司 | 一种包载卡非佐米的纳米粒制剂及其制备方法 |
| TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
| ES2842575T3 (es) | 2016-08-05 | 2021-07-14 | Amgen Inc | Síntesis de (S)-2-amino-4-metil-1-((R)-2-metiloxiran-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma |
| WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
| WO2018183686A1 (en) * | 2017-03-31 | 2018-10-04 | Valent Biosciences Llc | 1-aminocyclopropane-1-carboxylic acid polymorphs |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| AU2018370019C1 (en) | 2017-11-16 | 2025-01-30 | Amgen Inc. | Stable compositions of pegylated carfilzomib compounds |
| WO2019108285A1 (en) * | 2017-11-30 | 2019-06-06 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
| CN115279339A (zh) * | 2020-01-10 | 2022-11-01 | 美国安进公司 | 稳定的无环糊精的卡非佐米配制品 |
| WO2021257941A1 (en) * | 2020-06-19 | 2021-12-23 | Amgen Inc. | Methods of measuring carfilzomib |
| US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
| CN113406183B (zh) * | 2021-06-29 | 2024-04-23 | 常州磐诺仪器有限公司 | 基于离子淌度质谱仪高效识别青霉胺手性对映体的方法 |
| WO2025035020A2 (en) | 2023-08-09 | 2025-02-13 | Amgen Inc. | Methods of using carfilzomib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2260835E (pt) * | 2004-12-07 | 2013-05-28 | Onyx Therapeutics Inc | Composição para inibição do proteassoma |
| MY171061A (en) * | 2005-11-09 | 2019-09-24 | Onyx Therapeutics Inc | Compounds for enzyme inhibition |
| KR20170125413A (ko) * | 2007-10-04 | 2017-11-14 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
-
2012
- 2012-09-13 MY MYPI2017001061A patent/MY196510A/en unknown
- 2012-09-13 KR KR1020127028681A patent/KR20150007361A/ko not_active Withdrawn
- 2012-09-13 WO PCT/US2012/055127 patent/WO2013169282A1/en not_active Ceased
- 2012-09-13 MY MYPI2012005407A patent/MY165002A/en unknown
- 2012-09-13 EA EA201201519A patent/EA201201519A1/ru unknown
- 2012-09-13 US US13/614,829 patent/US20130303482A1/en not_active Abandoned
- 2012-09-13 AR ARP120103377A patent/AR087863A1/es not_active Application Discontinuation
- 2012-09-13 MX MX2012010891A patent/MX2012010891A/es not_active Application Discontinuation
- 2012-09-13 US US13/614,599 patent/US20130303465A1/en not_active Abandoned
- 2012-09-13 PH PH1/2012/502259A patent/PH12012502259A1/en unknown
- 2012-09-13 JP JP2015511431A patent/JP2015516416A/ja active Pending
- 2012-09-13 BR BR112012028726-5A patent/BR112012028726B1/pt active IP Right Grant
- 2012-09-13 CN CN201280001354.7A patent/CN103781490A/zh active Pending
- 2012-09-13 TW TW101133449A patent/TWI603737B/zh active
- 2012-09-13 AU AU2012238318A patent/AU2012238318B2/en active Active
- 2012-09-13 CA CA2793894A patent/CA2793894A1/en not_active Abandoned
- 2012-09-13 SG SG2012084075A patent/SG194417A1/en unknown
- 2012-09-26 EC ECSP12012167 patent/ECSP12012167A/es unknown
- 2012-09-26 CR CR20120485A patent/CR20120485A/es unknown
- 2012-09-27 DO DO2012000252A patent/DOP2012000252A/es unknown
- 2012-09-28 CO CO12170407A patent/CO6571868A2/es not_active Application Discontinuation
- 2012-10-02 ZA ZA2012/07384A patent/ZA201207384B/en unknown
- 2012-11-12 CU CU2012000159A patent/CU20120159A7/es unknown
-
2013
- 2013-12-04 MA MA36520A patent/MA35238B1/fr unknown
-
2022
- 2022-12-02 AR ARP220103323A patent/AR127861A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012028726B1 (pt) | 2021-07-13 |
| NZ602490A (en) | 2016-03-31 |
| JP2015516416A (ja) | 2015-06-11 |
| MY165002A (en) | 2018-02-28 |
| CR20120485A (es) | 2013-12-18 |
| AR127861A2 (es) | 2024-03-06 |
| PH12012502259A1 (en) | 2019-07-03 |
| AR087863A1 (es) | 2014-04-23 |
| AU2012238318B2 (en) | 2014-02-13 |
| SG194417A1 (en) | 2013-12-30 |
| EA201201519A1 (ru) | 2013-11-29 |
| TWI603737B (zh) | 2017-11-01 |
| MA35238B1 (fr) | 2014-07-03 |
| CO6571868A2 (es) | 2012-11-30 |
| MX2012010891A (es) | 2014-03-05 |
| CA2793894A1 (en) | 2013-11-08 |
| US20130303482A1 (en) | 2013-11-14 |
| DOP2012000252A (es) | 2013-12-31 |
| BR112012028726A2 (pt) | 2016-07-19 |
| AU2012238318A1 (en) | 2013-11-28 |
| TW201345543A (zh) | 2013-11-16 |
| CU20120159A7 (es) | 2014-03-26 |
| MY196510A (en) | 2023-04-18 |
| ZA201207384B (en) | 2018-12-19 |
| KR20150007361A (ko) | 2015-01-21 |
| CN103781490A (zh) | 2014-05-07 |
| US20130303465A1 (en) | 2013-11-14 |
| WO2013169282A1 (en) | 2013-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012167A (es) | Procedimientos para la formación de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico | |
| CL2017000969A1 (es) | Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014) | |
| CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
| GT201500051A (es) | Inhibidores de glucosilceramida sintasa | |
| BR112016012146A8 (pt) | derivados de aminopiridina como inibidores de quinase da família tam | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
| CU24397B1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| CO6630162A2 (es) | Derivados del ácido 1-amino -2-ciclopropiletilboronico | |
| CR20170352A (es) | Terapias de combinación para el tratamiento de cánceres | |
| CR20150250A (es) | Nuevos derivados de piridina | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| MX370900B (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas. | |
| CO7151512A2 (es) | Inhibidores del nampt | |
| AR093645A1 (es) | Una formulacion estabilizada de pemetrexed | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| UY34078A (es) | Composiciones farmacéuticas y métodos para tratar el cáncer | |
| CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
| MX2015006986A (es) | Solucion de trombina y metodos de uso de esta. | |
| BR112015030135A2 (pt) | ésteres de ácidos oligo-hidróxi carboxílicos e seu uso | |
| UY34829A (es) | Nueva dosificación y formulación | |
| BR112014019220A8 (pt) | Novos derivados de pirrolidina | |
| UA119441C2 (uk) | Посилювачі водорозчинності на основі глікогену | |
| MX2015016603A (es) | Composiciones de corticosteroides. |